TrialInternational journal of clinical oncology2021

Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.

Yoichiro Yoshida et al.PubMed ↗Publisher ↗

No numbers read from the abstract.